Spouting Rock Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Spouting Rock Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$246K	Sell	3,445 -5,774	-63%	-$341K	0.09%	101
2023 Q3	$552K	Hold	9,219	–	–	0.18%	83
2023 Q2	$665K	Hold	9,219	–	–	0.24%	83
2023 Q1	$678K	Buy	+9,219	New	+$655K	0.24%	80
2022 Q4	–	Sell	-4,242	Closed	-$228K	–	160
2022 Q3	$228K	Buy	+4,242	New	+$249K	0.18%	118
2021 Q2	–	Sell	-2,118	Closed	-$201K	–	224
2021 Q1	$201K	Buy	+2,118	New	+$200K	0.06%	201
2020 Q4	–	Sell	-27,070	Closed	-$1.61M	–	186
2020 Q3	$1.61M	Buy	27,070 +3,818	+16%	+$261K	0.77%	34
2020 Q2	$1.62M	Buy	23,252 +6,162	+36%	+$391K	0.77%	32
2020 Q1	$775K	Sell	17,090 -6,897	-29%	-$391K	0.54%	52
2019 Q4	$1.56M	Buy	+23,987	New	+$1.6M	0.4%	73

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Spouting Rock Asset Management's LGND Position: Q4 2023 in Review

Spouting Rock Asset Management reduced its Ligand Pharmaceuticals (LGND) stake by 63% in Q4 2023, selling an estimated $341K and leaving 3,445 shares worth $246K. The position accounts for 0.09% of the portfolio, ranked #101.

Spouting Rock Asset Management first reported a position in LGND in Q4 2019 and has held it in 10 quarters since. The position peaked at $1.62M in Q2 2020. 211 funds tracked by Wall St. Rank hold LGND as of Q4 2023.

Spouting Rock Asset Management held 3,445 shares of Ligand Pharmaceuticals worth $246K as of Q4 2023.
Spouting Rock Asset Management sold 5,774 Ligand Pharmaceuticals shares in Q4 2023, an estimated $341K.
Ligand Pharmaceuticals made up 0.09% of Spouting Rock Asset Management's portfolio in Q4 2023, its #101 holding.
Spouting Rock Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2019 and has held it in 10 quarters since.
Spouting Rock Asset Management's Ligand Pharmaceuticals position peaked at $1.62M in Q2 2020.
211 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2023.

Based on Spouting Rock Asset Management's 13F filing for Q4 2023, filed 16 Feb 2024.